PD-L1 Biomarker Testing Market
Market Insights on PD-L1 Biomarker Testing covering sales outlook, demand forecast & up-to-date key trends
PD-L1 Biomarker Testing Market By Product (PD-L1 22C3 Assay Kit, PD-L1 28-8 Assay Kit, PD-L1 SP142 Assay Kit, PD-L1 263 Assay Kit), Indication (NSCLS, Melanoma, Renal Cell Carcinoma, Gastrointestinal Tract Malignancy, Haematological Malignancies, Ovarian Cancer) & Region - Forecast 2022 - 2032
PD-L1 Biomarker Testing Market Outlook (2022-2032)
[318 Pages Report] The global PD-L1 biomarker testing market is projected to reach a valuation of US$ 597.9 Mn in 2022, with demand increasing at a robust 9.4% CAGR over the forecast period. Against this backdrop, the market valuation will total US$ 1.46 Bn by 2032.
|
Data Points |
Market Insights |
|
PD-L1 Biomarker Testing Market Value (2021) |
US$ 541.6 Mn |
|
PD-L1 Biomarker Testing Market Estimated Value (2022) |
US$ 597.9 Mn |
|
PD-L1 Biomarker Testing Market Projected Value (2032) |
US$ 1.46 Bn |
|
PD-L1 Biomarker Testing Market Value-based CAGR (2022-2032) |
9.4% |
|
PD-L1 Biomarker Testing Market Share of Top 5 Countries |
75.1% |
|
PD-L1 Biomarker Testing Market Key Players |
F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Abcam plc and Shuwein Biotech Co. Ltd. |
As per Future Market Insights (FMI), total sales in the NSCLS indications segment held about 61.9% of the global PD-L1 biomarker testing market share in 2021.
Manufacturers operating in the market are developing comprehensive cancer indications for available licensed biologics. Strategic approaches followed by the key players include an extension of indications through conduction of additional clinical investigations on the existing licensed biologics candidate.
Rising research activities for the treatment of several cancer indications are expected to bode well for the market. Increasing applications of biomarker testing across abundant and notorious tumour types, including trends in earlier-stage disease is anticipated to provide opportunities for key players to invest and research in the biomarker testing market.
The PD-L1 biomarker testing market accounted for nearly 2.0% of the global diagnostic biomarkers market worth US$ 30.1 Bn in 2021.
Let us know your requirement to get
100% FREE customization
Sales Analysis Of PD-L1 Biomarker Testing From 2016 To 2020 Vs Market Outlook For 2021 To 2032
PD-L1 biomarker testing is identified as an early biomarker of immunotherapy clinical trials, which is a protein that indicates tumour presence. These tests are one of the most reliable tests for tumour detection in the market currently.
The reliability of testing is based on the presence of unique levels of PD-L1 protein in each individual, thus making it a dependable testing method in oncology management. Cancer diagnostics and analysis use PD-L1 biomarkers during testing to detect early stages of non-small cell lung cancer (NSCLS) and melanoma.
Rising prevalence of lung cancer worldwide is underpinning the need for effective biomarker tests. Increasing consumption of tobacco and smoking owing to changing lifestyles and stress is increasing the incidence of lung cancer.
Additionally, persistent low quality of air, presence of carcinogenic agents in the environment and air pollution are the major contributors for the high prevalence of lung associated cancers, which is driving demand for reliable PD-L1 biomarker tests.
Rising awareness among the population regarding early cancer detection and diagnosis is propelling sales in the market. Increasing availability of high quality immunotherapy products globally will augment the growth in the market in the forthcoming years.
The prevalence of adverse conditions such as cancer relapse linked to frequent chemotherapy sessions and organ failure is spurring demand for advanced and novel technological solutions within the healthcare domain. This has resulted in higher reliance on cancer immunotherapy, which in turn is expected to drive sales of PD-L1 biomarker testing.
Backed by the aforementioned factors, sales in the market are projected to increase at a 9.4% CAGR, creating an absolute incremental opportunity of US$ 61.7 Mn over the forecast period.
What Are The Key Opportunities For PD-L1 Biomarker Testing Manufacturers?
The ongoing development of novel products and technologies with appropriate licensing for utilization is anticipated to propel the sales of PD-L1 biomarker testing in the forthcoming years. Strategic acquisitions between the leading players will provide significant opportunities for growth in terms of product differentiation.
Moreover, the development of reliable cancer screening and laboratory-based tests providing time effective diagnosis will bode well for the market. Growing applications of high medical value tests for more personalized medicine are expected to offer opportunities for growth for key market players.
Timely diagnosis of cancer is key, as misdiagnosis or delay in detection of lesions may lead to morbidity. Increasing usage of PD-L1 biomarker testing for early cancer diagnosis will augment the growth in the market over the forecast period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat Are The Factors Restraining Demand For PD-L1 Biomarker Testing?
Factors restraining the demand for PD-L1 biomarker testing include the challenges associated with testing and identification, validation of biomarkers and their implementation in molecular diagnostics. Moreover, trials associated with clone evolution and tumour heterogeneity identification, and testing of biomarkers is anticipated to have a negative impact on the growth in the market.
The shortage of qualified laboratory professionals will also hamper growth in the PD-L1 biomarker testing market as diagnostic laboratories utilize advanced equipment and automation. Despite the presence of advanced systems for ease of testing, critical errors related to the reliability of data across multiple platforms, as well as analogous challenges in analytical validation hamper will hamper sales.
Challenges in drug approval processes and tests by regulatory bodies and availability of limited reimbursement are significant barriers to molecular testing in several regions. These factors are favouring on-demand testing, which is set to impede the growth of the PD-L1 biomarker testing market in the coming years.
Country-Wise Insights
What is Driving the U.S. PD-L1 Biomarker Testing Market?
“Increasing Focus on Early Cancer Diagnosis in the U.S. Will Boost Sales of PD-L1 Biomarker Testing”
The U.S. dominated the North America PD-L1 biomarker testing market in 2021, holding 89.7% of the North America market share. High prevalence of lung cancer as well as associated chronic ailments in the country, along with increasing investments in the development of technologically advanced drugs and equipment in the oncology sector will boost the U.S. market over the forecast period.
Why is the U.K. PD-L1 Biomarker Testing Market Considered Lucrative?
“Growing Influx of Medical Tourism in the U.K. Will Bolster Demand for PD-L1 Biomarker Testing”
Sales in the U.K. are projected to increase at a 10% CAGR over the forecast period, accounting for a dominant share in the Europe PD-L1 testing market. The presence of governed predictive testing within the country by national and regional guidelines is anticipated to fuel sales in the market.
What Makes the China PD-L1 Biomarker Testing Market Attractive?
“Increasing Investments in the Medical Sector in China Will Boost Applications of PD-L1 Biomarker Testing”
As per FMI, China held 52.9% of the East Asia PD-L1 biomarker testing market in 2021, and sales are projected to increase at a 10.9% CAGR over the forecast period. Rising incidence of cancer cases in the country is underpinning the demand for PD-L1 biomarker testing.
Statistics presented by GLOBOCAN 2018 show that about 4,285,033 new cancer cases were diagnosed in China in 2018, which included 2,366,010 males and 1,919,023 females. These metrics support the transitive efforts by the country to present biomarker testing into the overall healthcare structure.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Which PD-L1 Biomarker Testing Product is Considered Highly Sought-After?
“Sales of PD-L1 22C3 Assay Kits Will Gain Traction”
Based on product type, demand in the PD-L1 22C3 assay kit segment is projected to increase at a 10.2% CAGR over the assessment period, accounting for 53% of the total market share by 2032. The effectiveness of PD-L1 22C3 assays during testing of non-small cell lung cancer, and patients’ positive response to immune checkpoint inhibitors will boost sales in this segment over the forecast period.
Why are Sales of PD-L1 Biomarker Testing in NSCLs Rising?
“Rising Incidence of Lung Cancer Across the Globe is Driving Demand for PD-L1 Biomarker Testing”
By indications, sales in the NSCLS segment is projected to increase at a 10.1% CAGR over the forecast period. The segment accounted for 61% of the global market share in 2021, and the trend is expected to continue in the forthcoming years. The availability of PD-L1 protein is the only biomarker which can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
Which End User Benefits the Most by PD-L1 Biomarker Testing?
“Demand for PD-L1 Biomarker Testing in Cancer Research Institutes Will Remain high”
In terms of end user, total sales in the cancer research institutes accounted for about 43.2% of the global market share in 2021. With rising prevalence of cancer associated morbidity across the globe, the research and development activities for novel therapeutics for oncological indications within cancer research institutes is gaining traction.
Competitive Landscape
Key players are focusing on the development and launch of novel PD-L1 biomarkers for the treatment of different types of cancers. Market exclusivity and government incentives to promote new and innovative options for cancer treatment will create lucrative opportunities for market players.
Some recent developments include:
- In June 2020, Merck received the FDA approval for second application for KEYTRUDA® (pembrolizumab), for the treatment of patients of all age groups suffering from metastatic tumour mutational burden-high (TMB-H).
- In May 2020, Agilent Technologies' PD-L1 IHC 28-8 pharmDx was approved by the FDA for diagnosis of NSCLC.
Report Scope As Per PD-L1 Biomarker Testing Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2017-2021 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa |
|
Key Countries Covered |
The U.S., Canada, Brazil, Mexico, Argentina, Germany, the U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa and South Africa |
|
Key Market Segments Covered |
Product, Indication, End User and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered In PD-L1 Biomarker Testing Industry Research
By Product:
- PD-L1 22C3 Assay Kit
- PD-L1 28-8 Assay Kit
- PD-L1 SP142 Assay Kit
- PD-L1 263 Assay Kit
By Indication:
- NSCLS
- Melanoma
- Renal Cell Carcinoma
- Gastrointestinal tract Malignancy
- Haematological Malignancies
- Ovarian Cancer
- Other
By End User:
- Hospitals
- Diagnostic Laboratories
- Cancer Research Institutes
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
The global PD-L1 biomarker testing market will total US$ 597.9 Mn in 2022, and is set to expand 2.4X over the forecast period.
The PD-L1 biomarker testing market is expected to reach US$ 1.46 Bn by the end of 2032, with sales growing at a 9.4% CAGR.
Growing burden of cancer, higher adoption of immunotherapy, and increasing approval for checkpoint inhibitor for the treatment of numerous cancer types are some of the key trends expected to drive the market.
The U.S., the U.K., Canada, Germany, and China are expected to drive demand in the PD-L1 biomarker testing market.
North America is one of the key markets for PD-L1 biomarker testing, with the U.S. expected to account over 90% of the North America market share during the forecast period.
Demand for PD-L1 biomarker testing in Europe is expected to grow at a 8.6% CAGR over the forecast period.
F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Abcam plc and Shuwein Biotech Co. Ltd. are the key players operating in the PD-L1 biomarker testing market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap/Treatment Evolution Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Product USPs / Features
4.3. Strategic Promotional Strategies
5. COVID19 Crisis Analysis
5.1. Current COVID19 Statistics and Probable Future Impact
5.2. Current GDP Projection and Probable Impact
5.3. Current Economic Projection as compared to 2008 financial analysis
5.4. COVID19 and Impact Analysis
5.4.1. Revenue by Product
5.4.2. Revenue by Indication
5.4.3. Revenue by End User
5.4.4. Revenue by Country
5.5. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Market Background
6.1. Macro-Economic Factors
6.2. Forecast Factors - Relevance & Impact
6.2.1. Top Companies Historical Growth
6.2.2. Continuous Manufacturing Technology Innovation
6.2.3. Increasing Prevalence of Cancer
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
7. Global PD-L1 Biomarker Testing Demand (in Volume Units) Analysis 2017-2021 and Forecast, 2022-2032
7.1. Historical Market Volume (Units) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
8. Global PD-L1 Biomarker Testing Market - Pricing Analysis
8.1. Regional Pricing Analysis by Product
8.2. Global Average Pricing Analysis Benchmark
9. Global PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
9.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
9.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Opportunity Analysis, 2022-2032
10. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis by Product, 2017–2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Product, 2022-2032
10.3.1. PD-L1 22C3 Assay Kit
10.3.2. PD-L1 28-8 Assay Kit
10.3.3. PD-L1 SP142 Assay Kit
10.3.4. PD-L1 SP263 Assay Kit
10.4. Market Attractiveness Analysis by Product
11. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis by Indication, 2017–2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Indication, 2022-2032
11.3.1. Non-small Cell Lung Cancer (NSCLC)
11.3.2. Melanoma
11.3.3. Renal Cell Carcinoma
11.3.4. Gastrointestinal Tract Malignancies
11.3.5. Ovarian Cancer
11.3.6. Haematological Malignancies
11.4. Market Attractiveness Analysis by Indication
12. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis by End User, 2017–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by End User, 2022-2032
12.3.1. Hospitals
12.3.2. Diagnostic Laboratories
12.3.3. Specialty Clinics
12.4. Market Attractiveness Analysis by End User
13. Global PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032, by Region
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis by Region, 2017–2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2022-2032
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa
13.4. Market Attractiveness Analysis by Region
14. North America PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
14.3.1. by Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. by Product
14.3.3. by Indication
14.3.4. by End User
14.4. Market Attractiveness Analysis
14.5. Drivers and Restraints - Impact Analysis
15. Latin America PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
15.3.1. by Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. by Product
15.3.3. by Indication
15.3.4. by End User
15.4. Market Attractiveness Analysis
15.5. Drivers and Restraints - Impact Analysis
16. Europe PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
16.3.1. by Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. by Product
16.3.3. by Indication
16.3.4. by End User
16.4. Market Attractiveness Analysis
16.5. Drivers and Restraints - Impact Analysis
17. South Asia PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
17.3.1. by Country
17.3.1.1. India
17.3.1.2. Thailand
17.3.1.3. Indonesia
17.3.1.4. Malaysia
17.3.1.5. Rest of South Asia
17.3.2. by Product
17.3.3. by Indication
17.3.4. by End User
17.4. Market Attractiveness Analysis
17.5. Drivers and Restraints - Impact Analysis
18. East Asia PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
18.3.1. by Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. by Product
18.3.3. by Indication
18.3.4. by End User
18.4. Market Attractiveness Analysis
18.5. Drivers and Restraints - Impact Analysis
19. Oceania PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
19.3.1. by Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. by Product
19.3.3. by Indication
19.3.4. by End User
19.4. Market Attractiveness Analysis
19.5. Drivers and Restraints - Impact Analysis
20. Middle East and Africa PD-L1 Biomarker Testing Market Analysis 2017-2021 and Forecast 2022-2032
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2017–2021
20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
20.3.1. by Country
20.3.1.1. GCC Countries
20.3.1.2. South Africa
20.3.1.3. Northern Africa
20.3.1.4. Rest of Middle East and Africa
20.3.2. by Product
20.3.3. by Indication
20.3.4. by End User
20.4. Market Attractiveness Analysis
20.5. Drivers and Restraints - Impact Analysis
21. Key and Emerging Countries PD-L1 Biomarker Testing Market Analysis 2022 & 2032
21.1. Introduction
21.1.1. Market Value Proportion Analysis, by Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. PD-L1 Biomarker Testing Market Analysis
21.2.1. by Product
21.2.2. by Indication
21.2.3. by End User
21.3. Canada PD-L1 Biomarker Testing Market Analysis
21.3.1. by Product
21.3.2. by Indication
21.3.3. by End User
21.4. Brazil PD-L1 Biomarker Testing Market Analysis
21.4.1. by Product
21.4.2. by Indication
21.4.3. by End User
21.5. Mexico PD-L1 Biomarker Testing Market Analysis
21.5.1. by Product
21.5.2. by Indication
21.5.3. by End User
21.6. Germany PD-L1 Biomarker Testing Market Analysis
21.6.1. by Product
21.6.2. by Indication
21.6.3. by End User
21.7. Italy PD-L1 Biomarker Testing Market Analysis
21.7.1. by Product
21.7.2. by Indication
21.7.3. by End User
21.8. U.K PD-L1 Biomarker Testing Market Analysis
21.8.1. by Product
21.8.2. by Indication
21.8.3. by End User
21.9. Spain PD-L1 Biomarker Testing Market Analysis
21.9.1. by Product
21.9.2. by Indication
21.9.3. by End User
21.10. BENELUX PD-L1 Biomarker Testing Market Analysis
21.10.1. by Product
21.10.2. by Indication
21.10.3. by End User
21.11. Russia PD-L1 Biomarker Testing Market Analysis
21.11.1. by Product
21.11.2. by Indication
21.11.3. by End User
21.12. India PD-L1 Biomarker Testing Market Analysis
21.12.1. by Product
21.12.2. by Indication
21.12.3. by End User
21.13. Thailand PD-L1 Biomarker Testing Market Analysis
21.13.1. by Product
21.13.2. by Indication
21.13.3. by End User
21.14. Indonesia PD-L1 Biomarker Testing Market Analysis
21.14.1. by Product
21.14.2. by Indication
21.14.3. by End User
21.15. Malaysia PD-L1 Biomarker Testing Market Analysis
21.15.1. by Product
21.15.2. by Indication
21.15.3. by End User
21.16. China PD-L1 Biomarker Testing Market Analysis
21.16.1. by Product
21.16.2. by Indication
21.16.3. by End User
21.17. Japan PD-L1 Biomarker Testing Market Analysis
21.17.1. by Product
21.17.2. by Indication
21.17.3. by End User
21.18. South Korea PD-L1 Biomarker Testing Market Analysis
21.18.1. by Product
21.18.2. by Indication
21.18.3. by End User
21.19. Australia PD-L1 Biomarker Testing Market Analysis
21.19.1. by Product
21.19.2. by Indication
21.19.3. by End User
21.20. New Zealand PD-L1 Biomarker Testing Market Analysis
21.20.1. by Product
21.20.2. by Indication
21.20.3. by End User
21.21. GCC PD-L1 Biomarker Testing Market Analysis
21.21.1. by Product
21.21.2. by Indication
21.21.3. by End User
21.22. South Africa PD-L1 Biomarker Testing Market Analysis
21.22.1. by Product
21.22.2. by Indication
21.22.3. by End User
22. Market Structure Analysis
22.1. Market Share Analysis of Top Players
22.2. Market Presence Analysis
22.2.1. By Regional footprint of Players
22.2.2. Product foot print by Players
22.2.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. F. Hoffmann-La Roche Ltd
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Profitability by Market Segments (Product/Channel/Region)
23.3.1.4. Sales Footprint
23.3.1.5. Strategy Overview
23.3.1.5.1. Marketing Strategy
23.3.1.5.2. Product Strategy
23.3.1.5.3. Channel Strategy
23.3.2. Agilent Technologies, Inc.
23.3.3. Abcam plc
23.3.4. Shuwein Biotech Co. Ltd.
24. Assumptions and Acronyms Used
25. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global PD-L1 Biomarker Testing Market Analysis (US$) 2017–2021 and Forecast 2022–2032, by Product
Table 02(A): Global PD-L1 Biomarker Testing Market Volume (Unit) Analysis 2017–2021 and Forecast 2022–2032, By Product
Table 02(B): Global PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032
Table 03: Global PD-L1 Biomarker Testing Market Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 04: Global PD-L1 Biomarker Testing Market Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 05: Global PD-L1 Biomarker Testing Market Analysis 2017–2021 and Forecast 2022–2032, by Region
Table 06: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 07: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 08: North America PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 09: North America PD-L1 Biomarker Testing Number of Tests (Thousands)Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 10: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 11: North America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 12: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 13: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 14: Latin America PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 15: Latin America PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 16: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 17: Latin America PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 18: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 19: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 20: Europe PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 21: Europe PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 22: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 23: Europe PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 24: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 25: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 26: South Asia PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 27: South Asia PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 28: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 29: South Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 30: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 31: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 32: East Asia PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 33: East Asia PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 34: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 35: East Asia PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 36: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 37: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 38: Oceania PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 39: Oceania PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 40: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 41: Oceania PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Table 42: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Country
Table 43: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 44: MEA PD-L1 Biomarker Testing Market Volume (Units) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 45: MEA PD-L1 Biomarker Testing Market Number of Tests (Thousands) Analysis 2017–2021 and Forecast 2022–2032, by Product
Table 46: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by Indication
Table 47: MEA PD-L1 Biomarker Testing Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, by End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global PD-L1 Biomarker Testing Market Volume (Units) Analysis, 2017–2021
Figure 02: Global PD-L1 Biomarker Testing Market Volume (Units) & Y-o-Y Growth (%) Analysis, 2022–2032
Figure 03: PD-L1 Biomarker Testing, Pricing Analysis per unit (US$), in 2021
Figure 04: PD-L1 Biomarker Testing, Pricing Forecast per unit (US$), in 2032
Figure 05: Global PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 06: Global PD-L1 Biomarker Testing Market Forecast & Y-o-Y Growth, 2022–2032
Figure 07: Global PD-L1 Biomarker Testing Market Absolute $ Opportunity, 2022 –2032
Figure 08: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by Product
Figure 09: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by Product
Figure 10: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by Product
Figure 11: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by Indication
Figure 12: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by Indication
Figure 13: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by Indication
Figure 14: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by End User
Figure 14: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by End User
Figure 15: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by End User
Figure 17: Global PD-L1 Biomarker Testing Market Value Share (%) Analysis 2022 and 2032, by Region
Figure 18: Global PD-L1 Biomarker Testing Market Y-o-Y Growth (%) Analysis 2021-2032, by Region
Figure 19: Global PD-L1 Biomarker Testing Market Attractiveness Analysis 2022–2032, by Region
Figure 20: North America PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 21: North America PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 22: North America PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 23: North America PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 24: North America PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 25: North America PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 26: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 27: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 28: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 29: North America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 30: Latin America PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 31: Latin America PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 32: Latin America PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 33: Latin America PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 34: Latin America PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 35: Latin America PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 36: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 37: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 38: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 39: Latin America PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 40: Europe PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 41: Europe PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 42: Europe PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 43: Europe PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 44: Europe PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 45: Europe PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 46: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 47: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 48: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 49: Europe PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 50: South Asia PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 51: South Asia PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 52: South Asia PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 53: South Asia PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 54: South Asia PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 55: South Asia PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 56: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 57: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 58: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 59: South Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 60: East Asia PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 61: East Asia PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 62: East Asia PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 63: East Asia PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 64: East Asia PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 65: East Asia PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 66: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 67: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 68: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 69: East Asia PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 70: Oceania PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 71: Oceania PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 72: Oceania PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 73: Oceania PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 74: Oceania PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 75: Oceania PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 76: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 77: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 78: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 79: Oceania PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 80: MEA PD-L1 Biomarker Testing Market Value Analysis, 2017–2021
Figure 81: MEA PD-L1 Biomarker Testing Market Forecast & Y-o-Y growth, 2022–2032
Figure 82: MEA PD-L1 Biomarker Testing Market Value Share by Product (2022E)
Figure 83: MEA PD-L1 Biomarker Testing Market Value Share by Indication (2022E)
Figure 84: MEA PD-L1 Biomarker Testing Market Value Share by End User (2022E)
Figure 85: MEA PD-L1 Biomarker Testing Market Value Share by Country (2022E)
Figure 86: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by Product
Figure 87: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by Indication
Figure 88: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by End User
Figure 89: MEA PD-L1 Biomarker Testing Market Attractiveness Analysis, by Country
Figure 90: Global PD-L1 Biomarker Testing Market Value Proportion Analysis, by Top Countries, 2022
Figure 91: Global PD-L1 Biomarker Testing Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2022-2032
Figure 92: U.S. Market Value Proportion Analysis
Figure 93: U.S. PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 94: U.S. PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 95: U.S. PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 96: Global Vs U.S. Growth Comparison
Figure 97: Canada Market Value Proportion Analysis
Figure 98: Canada PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 99: Canada PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 100: Canada PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 101: Global Vs Canada Growth Comparison
Figure 102: Brazil Market Value Proportion Analysis
Figure 103: Brazil PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 104: Brazil PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 105: Brazil PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 106: Global Vs Brazil Growth Comparison
Figure 107: Mexico Market Value Proportion Analysis
Figure 108: Mexico PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 109: Mexico PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 110: Mexico PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 111: Global Vs Mexico Growth Comparison
Figure 112: Argentina Market Value Proportion Analysis
Figure 113: Argentina PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 114: Argentina PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 115: Argentina PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 116: Global Vs Argentina Growth Comparison
Figure 117: U.K Market Value Proportion Analysis
Figure 118: U.K PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 119: U.K PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 120: U.K PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 121: Global Vs U.K Growth Comparison
Figure 122: Germany Market Value Proportion Analysis
Figure 123: Germany PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 124: Germany PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 125: Germany PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 126: Global Vs Germany Growth Comparison
Figure 127: France Market Value Proportion Analysis
Figure 128: France PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 129: France PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 130: France PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 131: Global Vs France Growth Comparison
Figure 132: Italy Market Value Proportion Analysis
Figure 133: Italy PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 134: Italy PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 135: Italy PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 136: Global Vs Italy Growth Comparison
Figure 137: Spain Market Value Proportion Analysis
Figure 138: Spain PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 139: Spain PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 140: Spain PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 141: Global Vs Spain Growth Comparison
Figure 142: Russia Market Value Proportion Analysis
Figure 143: Russia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 144: Russia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 145: Russia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 146: Global Vs Russia Growth Comparison
Figure 147: BENULUX Market Value Proportion Analysis
Figure 148: BENULUX PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 149: BENULUX PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 150: BENULUX PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 151: Global Vs BENELUX Growth Comparison
Figure 152: India Market Value Proportion Analysis
Figure 153: India PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 154: India PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 155: India PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 156: Global Vs India Argentina Growth Comparison
Figure 157: Thailand Market Value Proportion Analysis
Figure 158: Thailand PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 159: Thailand PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 160: Thailand PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 161: Global Vs Thailand Growth Comparison
Figure 162: Malaysia Market Value Proportion Analysis
Figure 163: Malaysia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 164: Malaysia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 165: Malaysia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 166: Global Vs Malaysia Growth Comparison
Figure 167: Indonesia Market Value Proportion Analysis
Figure 168: Indonesia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 169: Indonesia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 170: Indonesia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 171: Global Vs Indonesia Growth Comparison
Figure 172: China Market Value Proportion Analysis
Figure 173: China PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 174: China PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 175: China PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 176: Global Vs China Growth Comparison
Figure 177: Japan Market Value Proportion Analysis
Figure 178: Japan PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 179: Japan PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 180: Japan PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 181: Global Vs Japan Growth Comparison
Figure 182: South Korea Market Value Proportion Analysis
Figure 183: South Korea PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 184: South Korea PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 185: South Korea PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 186: Global Vs South Korea Growth Comparison
Figure 187: Australia Market Value Proportion Analysis
Figure 188: Australia PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 189: Australia PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 190: Australia PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 191: Global Vs Australia Growth Comparison
Figure 192: New Zealand Market Value Proportion Analysis
Figure 193: New Zealand PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 194: New Zealand PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 195: New Zealand PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 196: Global Vs New Zealand Growth Comparison
Figure 197: Turkey Market Value Proportion Analysis
Figure 198: Turkey PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 199: Turkey PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 200: Turkey PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 201: Global Vs Turkey Growth Comparison
Figure 202: GCC Countries Market Value Proportion Analysis
Figure 203: GCC Countries PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 204: GCC Countries PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 205: GCC Countries PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 206: Global Vs GCC Countries Growth Comparison
Figure 207: South Africa Market Value Proportion Analysis
Figure 208: South Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 209: South Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 210: South Africa PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 211: Global Vs South Africa Growth Comparison
Figure 212: North Africa Market Value Proportion Analysis
Figure 213: North Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Product, 2022 & 2032
Figure 214: North Africa PD-L1 Biomarker Testing Market Share Analysis (%) by Indication, 2022 & 2032
Figure 215: North Africa PD-L1 Biomarker Testing Market Share Analysis (%) by End User, 2022 & 2032
Figure 216: Global Vs North Africa Growth Comparison
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
